Abstracts tagged "ANCA"

Abstract Number: 734 • 2013 ACR/ARHP Annual Meeting
The Significance Of Anti-Myeloperoxidase and Anti-Proteinase 3 Antibodies In The Absence Of Anti-Neutrophil Cytoplasmic Antibody Immunofluorescence Positivity
Deepak A. Rao¹, Joseph F. Merola¹, William R. O'Brien¹, Kevin Wei¹, Samuel U. Takvorian², Paul F. Dellaripa³ and Peter H. Schur¹, ¹Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Internal Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ³Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Identification of serum anti-neutrophil cytoplasmic antibodies (ANCA) for the detection of ANCA-associated vasculitis (AAV) is often performed by screening with indirect immunofluorescence (IF), followed…
Abstract Number: 736 • 2013 ACR/ARHP Annual Meeting
Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Associated With Systemic Sclerosis In Japan: A Review Of The Literature
Natsumi Nagao¹, Yuri Sadanaga¹, Satoko Tashiro¹, Rie Suematsu¹, Syuichi Koarada¹, Akihide Ohta² and Yoshifumi Tada¹, ¹Rheumatology, Saga University, Saga, Japan, ²Nursing, Saga University, Saga, Japan
Background/Purpose: Cases of Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) during the course of systemic sclerosis (SSc) have recently been reported. Japanese cases of AAV associated…
Abstract Number: 149 • 2013 ACR/ARHP Annual Meeting
Comparative Proteomic Analysis Of Neutrophils From Patients With Microscopic Polyangiitis and Granulomatosis With Polyangiitis
Teisuke Uchida¹, Kohei Nagai², Toshiyuki Sato³, Nobuko Iizuka³, Mitsumi Arito³, Yukiko Takakuwa⁴, Hiromasa Nakano⁴, Seido Ooka⁴, Manae Kurokawa³, Naoya Suematsu³, Kazuki Okamoto³, Shoichi Ozaki⁵ and Tomohiro Kato³, ¹Division of Rheumatology and Allergy, Department of Internal Medicine, St. Marianna University School of Medicine, kawasaki, Japan, ²Department of Genetic Engineering, Faculty of Biology-Oriented Science and Technology, Kinki University, Wakayama, Japan, ³Clinical Proteomics and Molecular Medicine, St. Marianna University Graduate School of Medicine, Kawasaki, Japan, ⁴Division of Rheumatology and Allergy, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, ⁵Division of Rheumatology and Allergy, Department of Internal Medicine, St. Marianna University School of Medicine, St. Marianna University School of Medicine, Kawasaki, Japan
Background/Purpose: Both microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA) belong to ANCA-associated vasculitis (AAV), in which neutrophils are thought to be involved in their…
Abstract Number: 738 • 2013 ACR/ARHP Annual Meeting
Pulmonary Fibrosis In ANCA-Associated Vasculitis
Cloé Comarmond¹, Bruno Crestani², Abdellatif Tazi³, Baptiste Hervier⁴, Sylvain Adam-Marchand⁵, Hilario Nunes⁶, Fleur Cohen-Aubart⁷, Marie Wislez⁸, Jacques Cadranel⁸, Bruno Housset⁹, Célia Lloret-Linares¹⁰, Pascal Sève¹¹, Christian Pagnoux¹², Sébastien Abad¹³, Juliette Camuset¹⁴, Boris Bienvenu¹⁵, Michael Duruisseaux¹⁶, Eric Hachulla¹⁷, Jean-Benoît Arlet¹⁸, Mohamed Hamidou¹⁹, Alfred Mahr²⁰, Anne-Laure Brun²¹, Philippe Grenier²¹, Patrice Cacoub²² and David Saadoun²³, ¹Internal Medicine and Clinical Imunology, Referal Center for Autoimmune diseases, Internal Medicine and Clinical Imunology, Hôpital Pitié Salpétrière, Paris, France, ²Pneumology A, Hôpital Bichat, Paris, France, ³Hôpital Saint-Louis, Paris, France, ⁴Internal Medicine & Clinical Immunology Dpt, Pitié-Salpêtrière Hospital, APHP, Paris, France, ⁵Pneumology, Centre Hospitalier Universitaire de Tours, Tours, France, ⁶Department of Pneumology, Avicenne Hospital (AP-HP), Bobigny, France, ⁷Internal Medicine Dpt 2, Pitié-Salpêtrière Hospital, APHP, Paris, France, ⁸Pneumology, Hôpital Tenon, Paris, France, ⁹Pneumology, Centre Hospitalier Intercommunal de Créteil, Créteil, France, ¹⁰Médecine Interne A, Hôpital Lariboisière, Paris, France, ¹¹Internal medicine, CHU Lyon, Lyon, France, ¹²Rheumatology, Mount Sinai Hospital, Toronto, Canada, Toronto, ON, Canada, ¹³Internal Medicine, Avicenne Hospital, Bobigny, France, ¹⁴Pneumology, Centre Hospitalier Victor Dupouy, Argenteuil, France, ¹⁵Division of Internal Medicine, Centre Hospitalier Régional Universitaire de Caen, Côte de Nacre, Caen, France, Caen, France, ¹⁶Pneumology, CHU de Grenoble, Grenoble, France, ¹⁷Internal Medicine, Lille CEDEX, France, ¹⁸Internal Medicine, HEGP, Paris, France, ¹⁹Internal Medicine Department, Nantes University Hospital, Nantes, France, ²⁰Department of Internal Medicine, Hospital Saint-Louis, Paris, France, ²¹Radiology, Hôpital Pitié-Salpêtrière, Paris, France, ²²Médecine Interne 2, Hopital Pitié-Salpétrière, Paris, France, ²³Groupe Hospitalier Pitié Salpétrière, Service de Médecine Interne, DHU i2B, Paris, France
Background/Purpose: The association of pulmonary fibrosis (PF) with anti neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis (AAV), especially microscopic polyangiitis (MPA), is rare but related to poor…
Abstract Number: 741 • 2013 ACR/ARHP Annual Meeting
Granulomatosis With Polyangiitis Central Nervous System Involvement: Presentation and Management
Gonzalo De Luna^1,2, Benjamin Terrier³, Pierre Kaminsky⁴, Francois Maurier⁵, Roser Solans⁶, Raphaèle Seror⁷, Xavier Puéchal⁸, Luc Mouthon⁹ and Loic Guillevin¹⁰, ¹Medecine Interne, Cochin University Hospital, Paris, France, ²Internal Medicine, Hospital Ramon y Cajal, Madrid, Spain, ³Internal Medicine, Cochin University Hospital, Paris, France, ⁴Université de Lorraine, Nancy, F-54000, France; CHU de Nancy, Orphan disease unit, Nancy, F-54000, France;, Nancy, France, ⁵HP Metz Belle Isle Hospital, Department of Internal Medicine, Metz, France, ⁶Autoimmune Systemic Diseases Unit, Department of Internal Medicine, Hospital Vall d'Hebron, Autonomous University of Barcelona, Barcelona, Spain, ⁷Rheumatology, Bicetre university hospital, LE Kremlin-Bicetre, France, ⁸National Referral Center for Rare Systemic Auto-immune Diseases, Hôpital Cochin, AP-HP, Université Paris Descartes, Sorbonne Paris Cité, Paris, France, ⁹Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, Paris, France, ¹⁰Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France
Background/Purpose: Granulomatosis with polyangiitis (GPA), a small-sized–vessel vasculitis, commonly involves ear, nose & throat (ENT), lungs and kidneys, and, more rarely, the central nervous system…
Abstract Number: 2782 • 2013 ACR/ARHP Annual Meeting
Retreatment With Rituximab In The Rituximab In ANCA-Associated Vasculitis (RAVE) Trial
Eli Miloslavsky¹, Ulrich Specks², Peter A Merkel³, Philip Seo⁴, Robert F. Spiera⁵, Carol A. Langford⁶, Gary S. Hoffman⁷, Cees G.M. Kallenberg⁸, E. William St Clair⁹, Nadia Tchao¹⁰, Linna Ding¹¹, David Ikle¹², Brett Jepson¹², Paul Brunetta¹³ and John H. Stone¹⁴, ¹Division of Rheumatology, Massachusetts General Hopsital, Boston, MA, ²Mayo Clinic, Rochester, MN, ³Division of Rheumatology, University of Pennsylvania and VA Medical Center, Philadelphia, PA, ⁴Rheumatology Division, Johns Hopkins Vasculitis Center, Johns Hopkins University, Baltimore, MD, ⁵Rheumatology, Hospital for Special Surgery, New York, NY, ⁶Center for Vasculitis Care and Research, Cleveland Clinic, Cleveland, OH, ⁷Center for Vasculitis Care and Research, Cleveland Clinic Foundation, Cleveland, OH, ⁸Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands, ⁹Medicine, Duke Unversity Medical Center, Durham, NC, ¹⁰Immune Tolerance Network, Bethesda, MD, ¹¹NIAID, Bethesda, MD, ¹²Rho, Chapel Hill, NC, ¹³Biotherapeutics, Genentech, So San Francisco, CA, ¹⁴Rheumatology, Massachusetts General Hospital, Boston, MA
Background/Purpose: Retrospective studies have demonstrated that repeat rituximab treatment may be effective in re-inducing remission in relapsing ANCA-associated vasculitis. We analyzed data from the Rituximab…
Abstract Number: 743 • 2013 ACR/ARHP Annual Meeting
Efficacy Of Rituximab For Otolaryngologic (ENT) Manifestations Of Granulomatosis With Polyangiitis (GPA, Wegener’s granulomatosis)
Lindsay Lally¹, Robert Lebovics², Wei-Ti Huang³ and Robert F. Spiera¹, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Otolaryngology, St. Luke's-Roosevelt Hospital Center, New York, NY, ³Biostatistics, Hospital for Special Surgery, New York, NY
Background/Purpose: ENT involvement is the most prevalent manifestation of GPA. Rituximab (RTX) is a proven effective remission induction therapy for severe GPA with vasculitic manifestations. …
Abstract Number: 2784 • 2013 ACR/ARHP Annual Meeting
Mononeuritis Multiplex Predicts The Need For Immunosuppressive Or Immunomodulatory Drugs For Eosinophilic Granulomatosis With Polyangiitis, Polyarteritis Nodosa and Microscopic Polyangiitis Patients Without Poor-Prognosis Factors
Maxime Samson¹, Xavier Puéchal², Hervé Devilliers³, Camillo Ribi⁴, Pascal Cohen⁵, Boris Bienvenu⁶, Christian Pagnoux⁷, Luc Mouthon², Loic Guillevin⁸ and French Vasculitis Study Group (FVSG)², ¹Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France; Internal Medicine and Clinical Immunology, Dijon University Hospital, Dijon, France, ²Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, Paris, France, ³Dijon University Hospital, Department of internal medicine and systemic diseases, Dijon, France, ⁴Immunology and Allergology, Internal Medicine, University Hospitals of Geneva, Geneva, Switzerland, Geneva, Switzerland, ⁵National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, Paris, France, ⁶Division of Internal Medicine, Centre Hospitalier Régional Universitaire de Caen, Côte de Nacre, Caen, France, Caen, France, ⁷Rheumatology, Mount Sinai Hospital, Toronto, Canada, Toronto, ON, Canada, ⁸Department of Internal Medicine,, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France
Background/Purpose: Patients with eosinophilic granulomatosis with polyangiitis (EGPA), polyarteritis nodosa (PAN) or microscopic polyangiitis (MPA) without poor-prognosis factors, as defined by their 1996 Five-Factor Scores…
Abstract Number: 747 • 2013 ACR/ARHP Annual Meeting
Efficacy Of Glucocorticoids To Treat Limited Flares In ANCA-Associated Vasculitis
Eli Miloslavsky¹, Ulrich Specks², Peter A. Merkel³, Philip Seo⁴, Robert F. Spiera⁵, Carol A. Langford⁶, Gary S. Hoffman⁷, Cees G.M. Kallenberg⁸, E. William St. Clair⁹, Nadia Tchao¹⁰, Linna Ding¹¹, David Ikle¹², Brett Jepson¹², Paul Brunetta¹³ and John H. Stone¹⁴, ¹Division of Rheumatology, Massachusetts General Hopsital, Boston, MA, ²Mayo Clinic, Rochester, MN, ³Division of Rheumatology, Vasculitis Center, University of Pennsylvania, Philadelphia, PA, ⁴Rheumatology Division, Johns Hopkins Vasculitis Center, Johns Hopkins University, Baltimore, MD, ⁵Rheumatology, Hospital for Special Surgery, New York, NY, ⁶Center for Vasculitis Care and Research, Cleveland Clinic, Cleveland, OH, ⁷Center for Vasculitis Care and Research, Cleveland Clinic Foundation, Cleveland, OH, ⁸Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands, ⁹Medicine, Duke University Medical Center, Durham, NC, ¹⁰Immune Tolerance Network, Bethesda, MD, ¹¹NIAID, Bethesda, MD, ¹²Rho, Chapel Hill, NC, ¹³Biotherapeutics, Genentech, So San Francisco, CA, ¹⁴Rheumatology, Massachusetts General Hospital, Boston, MA
Background/Purpose: The great majority of patients with granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) achieve disease remission initially, but relapses occur in up to…
Abstract Number: 2785 • 2013 ACR/ARHP Annual Meeting
Urinary Inflammatory Cells Strongly Reflect the Disease Activity and Renal Function in Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis
Yoko Wada¹, Minoru Sakatsume², Masaaki Nakano³ and Ichiei Narita¹, ¹Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan, ²Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan, ³School of Health Sciences, Faculty of Medicine, Niigata University, Niigata, Japan
Background/Purpose: The antineutrophil cytoplasmic autoantibody (ANCA)- associated vasculitides (AAVs) include microscopic polyangiitis (MPA), granulomatosis with polyangitis (GPA; formerly Wegener’s), and eosinophilic granulomatosis with polyangitis (EGPA).…
Abstract Number: 1538 • 2012 ACR/ARHP Annual Meeting
ANCA-Associated Vasculitis in Hispanic Americans: An Unrecognized Severity
Ranadeep Mandhadi¹, Fadi Aldaghlawi², Asad Khan², Vajiha Irshad³, Joel A. Block² and Antoine Sreih⁴, ¹Mount Sinai Hospital, Chicago, IL, ²Rush University Medical Center, Chicago, IL, ³Internal Medicine, Stroger Hospital of Cook County, Chicago, IL, ⁴Medicine/Rheumatology, Rush University Medical Center, Chicago, IL
Background/Purpose: ANCA-associated vasculitis, once a disease thought to predominate in Caucasians, is now increasingly recognized in diverse ethnic populations. However, there has been little systematic…
Abstract Number: 1541 • 2012 ACR/ARHP Annual Meeting
Does Leflunomide Have a Place As Remission Maintenance Therapy in ANCA-Associated Vasculitis? A Bayesian Network Meta-Analysis with Hypothesis Driven Sensitivity Analyses to Adjust for Potential Biases
Glen S. Hazlewood¹, Claudia Metzler², George A. Tomlinson³, Wolfgang L. Gross⁴, Brian M. Feldman⁵, Loic Guillevin⁶ and Christian Pagnoux⁷, ¹Medicine, University of Toronto, Toronto, ON, Canada, ²University of Lubeck, Bad Branstedy, Germany, ³University of Toronto, Toronto, ON, Canada, ⁴Dept of Clinical Rheumatology, Medical University at Lubeck, Lubeck, Germany, ⁵Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ⁶Internal Medicine, Cochin University Hospital, Paris, France, ⁷Rheumatology, Mount Sinai Hospital, Toronto, Canada, Toronto, ON, Canada
Background/Purpose: Primary: To determine the relative treatment effects of maintenance therapy in adult patients with ANCA-associated vasculitis who have achieved remission, using a Bayesian network…
Abstract Number: 1542 • 2012 ACR/ARHP Annual Meeting
The Efficacy of Rituximab Vs Cyclophosphamide for Treatment of Renal Disease in ANCA-Associated Vasculitis: The RAVE Trial Geetha D, Fervenza FC for the RAVE-Itn Research Group
Duvuru Geetha¹ and Fernando Fervenza², ¹Nephrology, Johns Hopkins University, Baltimore, MD, ²Mayo Clinic, Rochester, MN
Background/Purpose: Rituximab (RTX) is non-inferior to cyclophosphamide (CYC) followed by azathioprine (AZA) for remission-induction in severe ANCA associated vasculitis (AAV) but details of outcomes among…
Abstract Number: 1543 • 2012 ACR/ARHP Annual Meeting
Rituximab for ANCA-Associated Vasculitis: A Meta-Analysis of Randomized Trials
Carolina Mejia¹ and Carlos J. Lozada², ¹Internal Medicine, Mount Sinai Medical Center, Miami, FL, ²Dept of Medicine/Rheumatology, University of Miami Miller School of Medicine, Miami, FL
Background/Purpose: Over the past 40 years, cyclophosphamide/glucocorticoids combination therapy has been the standard regimen for remission induction in ANCA-associated vasculitis.. Although a major advance in…
Abstract Number: 1545 • 2012 ACR/ARHP Annual Meeting
Long-Term Follow-up of 118 Polyarteritis Nodosa and Microscopic Polyangiitis without Poor-Prognosis Factors
Maxime Samson¹, Xavier Puechal², Hervé Devilliers³, Camillo Ribi⁴, Pascal Cohen⁵, Boris Bienvenu⁶, Christian Pagnoux⁷, Luc Mouthon⁸, Loic Guillevin⁹ and French Vasculitis Study Group FVSG¹⁰, ¹Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France; Internal Medicine and Clinical Immunology, Dijon University Hospital, Dijon, France, ²Internal Medicine, Hôpital Cochin, Paris, France, ³Internal medicine, Hôpital Général, Dijon, France, ⁴Internal Medicine, Hôpital Universitaire Cantonal de Genève, Geneve, Switzerland, ⁵National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, Paris, France, ⁶Division of Internal Medicine, Centre Hospitalier Régional Universitaire de Caen, Côte de Nacre, Caen, France, Caen, France, ⁷Rheumatology, Mount Sinai Hospital, Toronto, Canada, Toronto, ON, Canada, ⁸Internal Medicine, Hopital Cochim, Paris, France, ⁹Internal Medicine, Division of Internal Medicine, Hôpital Cochin, University Paris Descartes, Paris, France, ¹⁰Internal Medicine, Service de médecine interne, Centre de Références des Vascularites, Université Paris Descartes, APHP, Hôpital Cochin, 75005 Paris, France., Paris, France
Background/Purpose: Polyarteritis nodosa (PAN) and microscopic polyangiitis (MPA) are 2 vasculitides characterized by necrotizing inflammation of the vessel wall. They share several clinical features and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].